CORCEPT THERAPEUTICS INC APIC, Share-based Payment Arrangement, Increase for Cost Recognition
CORCEPT THERAPEUTICS INC (CORT) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $24.47 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Shareholders' Equity › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-07-29
- CORCEPT THERAPEUTICS INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $24.47M, a 25.94% increase year-over-year.
- CORCEPT THERAPEUTICS INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $21.71M, a 38.42% increase year-over-year.
- CORCEPT THERAPEUTICS INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $20.39M, a 42.70% increase year-over-year.
- CORCEPT THERAPEUTICS INC apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $19.43M, a 39.95% increase year-over-year.
- CORCEPT THERAPEUTICS INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $76.51M, a 37.33% increase from fiscal 2024.
- CORCEPT THERAPEUTICS INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $55.71M, a 21.17% increase from fiscal 2023.
- CORCEPT THERAPEUTICS INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $45.98M, a 8.14% increase from fiscal 2022.
- CORCEPT THERAPEUTICS INC apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $42.52M, a 1.51% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $24.47M 10-Q · filed 2026-07-29 | $46.18M derived: sum of 2 quarters · filed 2026-07-29 | ||
| 2026-03-31 | $21.71M 10-Q · filed 2026-07-29 | |||
| 2025-12-31 | $76.51M 10-K · filed 2026-02-24 | |||
| 2025-09-30 | $20.39M 10-Q · filed 2025-11-04 | $39.81M derived: sum of 2 quarters · filed 2026-07-29 | $55.50M derived: sum of 3 quarters · filed 2026-07-29 | |
| 2025-06-30 | $19.43M 10-Q · filed 2026-07-29 | $35.11M derived: sum of 2 quarters · filed 2026-07-29 | ||
| 2025-03-31 | $15.69M 10-Q · filed 2026-07-29 | |||
| 2024-12-31 | $55.71M 10-K · filed 2026-02-24 | |||
| 2024-09-30 | $14.29M 10-Q · filed 2025-11-04 | $28.17M derived: sum of 2 quarters · filed 2025-11-04 | $41.10M derived: sum of 3 quarters · filed 2025-11-04 | |
| 2024-06-30 | $13.88M 10-Q · filed 2025-11-04 | $26.81M derived: sum of 2 quarters · filed 2025-11-04 | ||
| 2024-03-31 | $12.93M 10-Q · filed 2025-11-04 | |||
| 2023-12-31 | $45.98M 10-K · filed 2026-02-24 | |||
| 2023-09-30 | $11.66M 10-Q · filed 2024-10-30 | $23.03M derived: sum of 2 quarters · filed 2024-10-30 | $34.00M derived: sum of 3 quarters · filed 2024-10-30 | |
| 2023-06-30 | $11.37M 10-Q · filed 2024-10-30 | $22.34M derived: sum of 2 quarters · filed 2024-10-30 | ||
| 2023-03-31 | $10.97M 10-Q · filed 2024-10-30 | |||
| 2022-12-31 | $42.52M 10-K · filed 2025-02-26 | |||
| 2022-09-30 | $10.63M 10-Q · filed 2023-11-01 | $21.29M derived: sum of 2 quarters · filed 2023-11-01 | $32.12M derived: sum of 3 quarters · filed 2023-11-01 | |
| 2022-06-30 | $10.66M 10-Q · filed 2023-11-01 | $21.49M derived: sum of 2 quarters · filed 2023-11-01 | ||
| 2022-03-31 | $10.82M 10-Q · filed 2023-11-01 | |||
| 2021-12-31 | $43.17M 10-K · filed 2024-02-15 | |||
| 2021-09-30 | $11.00M 10-Q · filed 2022-11-03 | $22.13M derived: sum of 2 quarters · filed 2022-11-03 | $32.27M derived: sum of 3 quarters · filed 2022-11-03 | |
| 2021-06-30 | $11.13M 10-Q · filed 2022-11-03 | $21.27M derived: sum of 2 quarters · filed 2022-11-03 | ||
| 2021-03-31 | $10.14M 10-Q · filed 2022-11-03 | |||
| 2020-09-30 | $8.76M 10-Q · filed 2021-11-03 | $17.30M derived: sum of 2 quarters · filed 2021-11-03 | $25.29M derived: sum of 3 quarters · filed 2021-11-03 | |
| 2020-06-30 | $8.55M 10-Q · filed 2021-11-03 | $16.54M derived: sum of 2 quarters · filed 2021-11-03 | ||
| 2020-03-31 | $7.99M 10-Q · filed 2021-11-03 | |||
| 2019-09-30 | $7.29M 10-Q · filed 2020-11-03 | $15.08M derived: sum of 2 quarters · filed 2020-11-03 | $21.81M derived: sum of 3 quarters · filed 2020-11-03 | |
| 2019-06-30 | $7.79M 10-Q · filed 2020-11-03 | $14.52M derived: sum of 2 quarters · filed 2020-11-03 | ||
| 2019-03-31 | $6.72M 10-Q · filed 2020-11-03 | |||
| 2018-09-30 | $6.51M 10-Q · filed 2019-11-07 | $12.53M derived: sum of 2 quarters · filed 2019-11-07 | $17.48M derived: sum of 3 quarters · filed 2019-11-07 | |
| 2018-06-30 | $6.02M 10-Q · filed 2019-11-07 | $10.97M derived: sum of 2 quarters · filed 2019-11-07 | ||
| 2018-03-31 | $4.95M 10-Q · filed 2019-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |